For the quarter ending 2025-09-30, BRTX made $11,800 in revenue. -$3,038,277 in net income. Net profit margin of -25748.11%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenues | 11,800 | 303,300 | 25,000 | 39,150 |
| Cost of goods sold | 10,570 | 8,729 | 2,909 | 1,669.5 |
| Gross profit | 1,230 | 294,571 | 22,091 | 37,480.5 |
| Research and development | 2,594,750 | 2,225,882 | 1,714,327 | 1,368,248.5 |
| General and administrative | 1,115,491 | 1,373,976 | 3,115,298 | 2,068,929 |
| Total operating expenses | 3,710,241 | 3,599,858 | 4,829,625 | 3,437,177.5 |
| Loss from operations | -3,709,011 | -3,305,287 | -4,807,534 | -3,399,697 |
| Interest income | 57,740 | 73,915 | 99,966 | 140,792.5 |
| Other income | 930 | 518 | 1,888 | 74,686.5 |
| Change in fair value of warrant liabilities | 612,064 | 574,591 | -634,119 | 398,667.5 |
| Gain on exchange of warrants | - | 0 | - | 855,849 |
| Total other income | 670,734 | 649,024 | -532,265 | 1,469,995.5 |
| Net loss | -3,038,277 | -2,656,263 | -5,339,799 | -1,929,701.5 |
| Net loss per share - basic | -0.33 | -0.3 | -0.64 | -0.265 |
| Net loss per share - diluted | -0.33 | -0.3 | -0.64 | -0.265 |
| Weighted average common shares outstanding - basic | 9,116,172 | 8,740,382 | 8,357,143 | -4,239,533 |
| Weighted average common shares outstanding - diluted | 9,116,172 | 8,740,382 | 8,357,143 | -4,239,533 |
BioRestorative Therapies, Inc. (BRTX)
BioRestorative Therapies, Inc. (BRTX)